Insider Selling: Heartflow (NASDAQ:HTFL) CEO Sells 22,562 Shares of Stock

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 22,562 shares of the business’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $29.12, for a total value of $657,005.44. Following the transaction, the chief executive officer owned 519,397 shares of the company’s stock, valued at $15,124,840.64. This trade represents a 4.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John C.M. Farquhar also recently made the following trade(s):

• On Friday, April 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $26.72, for a total transaction of $602,856.64.
• On Wednesday, March 18th, John C.M. Farquhar sold 9,725 shares of Heartflow stock. The stock was sold at an average price of $25.00, for a total transaction of $243,125.00.
• On Tuesday, March 10th, John C.M. Farquhar sold 12,837 shares of Heartflow stock. The shares were sold at an average price of $22.66, for a total transaction of $290,886.42.

Heartflow Stock Performance

Shares of HTFL stock traded up $1.78 during midday trading on Wednesday, reaching $31.20. 943,935 shares of the company were exchanged, compared to its average volume of 1,385,633. The company’s 50 day moving average price is $26.88 and its two-hundred day moving average price is $28.97. The company has a market cap of $2.69 billion and a P/E ratio of -15.68. Heartflow, Inc. has a 12 month low of $20.13 and a 12 month high of $41.22.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Canaccord Genuity Group increased their price target on Heartflow from $40.00 to $43.00 and gave the company a “buy” rating in a research note on Thursday, March 19th. JPMorgan Chase & Co. cut their price objective on Heartflow from $40.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday, March 19th. Wells Fargo & Company decreased their target price on Heartflow from $38.00 to $35.00 and set an “overweight” rating for the company in a research note on Thursday, March 19th. Finally, William Blair started coverage on shares of Heartflow in a research report on Monday, May 4th. They issued an “outperform” rating on the stock. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $37.67.

Institutional Investors Weigh In On Heartflow

Several large investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Heartflow during the fourth quarter valued at $27,000. Russell Investments Group Ltd. purchased a new position in Heartflow in the 4th quarter worth about $45,000. Legal & General Group Plc acquired a new stake in Heartflow during the 3rd quarter worth about $59,000. Strs Ohio purchased a new stake in Heartflow during the fourth quarter valued at about $99,000. Finally, Bessemer Group Inc. acquired a new position in shares of Heartflow in the first quarter worth about $126,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.